Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04269395 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
A Phase 3 study, sponsored by Galderma R&D.
- Terminated
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
NCT04269395 is a Phase 3 study that was terminated before completion, run by Galderma R&D. The registered enrollment target is 125 participants.
The verdict
NCT04269395, a Phase 3 study, was terminated before completion, sponsored by Galderma R&D.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
Study Summary
The primary purpose for this study is to assess recurrence of Actinic Keratosis in participants achieving complete response treated in earlier study.
Interventions
- DRUG Vehicle cream
- DRUG MAL Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2020-04-07 |
| Est. Completion | 2021-09-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04269395
The ClinicalTrials.gov registry entry for NCT04269395 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle cream is the first listed.
NCT04269395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04269395 about?
NCT04269395 is a clinical study titled "A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study". The primary purpose for this study is to assess recurrence of Actinic Keratosis in participants achieving complete response treated in earlier study.
What is the current status of trial NCT04269395?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2020-04-07. Estimated completion is 2021-09-01.
What interventions are being tested in trial NCT04269395?
The interventions under investigation include: Vehicle cream (DRUG), MAL Cream (DRUG).
Who is sponsoring clinical trial NCT04269395?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.